Impower010 nct02486718
Witryna(Denver September 10, 2024 9 a.m. GMT/10 a.m. CDT/11 a.m. EDT)-- The Phase III IMpower010 trial evaluating atezolizumab vs best supportive care after surgical … WitrynaEnriqueta Felip, MD, PhD, Vall d'Hebron Institute of Oncology, Barcelona, Spain, shares overall survival (OS) interim analysis of IMpower010, a Phase III stu...
Impower010 nct02486718
Did you know?
WitrynaIMpower010 (NCT02486718) showed a statistically significant benefit in primary-endpoint disease-free survival (DFS) with adjuvant atezo vs BSC in resected stage II … Witryna22 paź 2024 · Adjuvant atezolizumab was approved for use in this indication on October 15, 2024, based on findings from the phase 3 IMpower010 trial (NCT02486718). 2 Results indicated that the median disease ...
Witryna9 paź 2024 · IMpower010 is registered with ClinicalTrials.gov, NCT02486718 (active, not recruiting). Findings Between Oct 7, 2015, and Sept 19, 2024, 1280 patients were enrolled after complete resection. 1269 received adjuvant chemotherapy, of whom 1005 patients were eligible for randomisation to atezolizumab (n=507) or best supportive … WitrynaIMpower010 (NCT02486718). 40: Patients with stage IB–IIIA NSCLC: A phase III, multicenter, open-label, randomized study: In patients with stage IB-IIIA NSCLC following resection and adjuvant chemotherapy, the study compares the efficacy and safety of 16 cycles of atezolizumab treatment compared with supportive care. Primary outcomes: …
Witryna1 wrz 2024 · IMpower010 (NCT02486718) was the first Phase III immunotherapy study to show a statistically significant disease-free survival (DFS) benefit with adjuvant … WitrynaIMpower010 (NCT02486718) showed that adjuvant atezo improved disease-free survival (DFS) vs BSC in pts with PD-L1 tumour cell (TC) ≥1% stage II-IIIA NSCLC. While a ctDNA positive (+) status post-surgery (Post-OP ctDNA) conferred poor prognosis, atezo was beneficial vs BSC irrespective of Post-OP ctDNA status (Zhou ESMO-IO 2024). ...
WitrynaPrevious findings from the Phase III IMpower010 ( NCT02486718) trial demonstrated a statistically significant improved disease-free survival (DFS) with atezolizumab compared to best supportive care (BSC) in patients with resected PD-L1 TC ≥1% stage II-IIIA non-small cell lung cancer (NSCLC) following platinum-based chemotherapy. 5 The …
Witryna1 wrz 2024 · IMpower010 (NCT02486718) was the first Phase III immunotherapy study to show a statistically significant disease-free survival (DFS) benefit with adjuvant atezolizumab vs best supportive care (BSC) in resected NSCLC following platinum-based chemotherapy (Felip et al. Lancet 2024). greenvale united soccer clubWitryna28 maj 2024 · We report the primary disease-free survival (DFS) results from the pre-planned interim analysis of IMpower010, a randomized phase 3 open-label trial of … greenvale vic weatherWitryna20 wrz 2024 · IMpower010 showed a disease-free survival benefit with atezolizumab versus best supportive care after adjuvant chemotherapy in patients with resected stage II-IIIA NSCLC, with pronounced benefit in the subgroup whose tumours expressed PD-L1 on 1% or more of tumour cells, and no new safety signals. greenvale ny postal codeWitryna中华医学杂志, 2024,103(14): 1074-1081.DOI: 10.3760/cma.j.cn112137-20241212-02628 fnf kbh tom and jerryWitrynaIMpower010 (NCT02486718) showed that adjuvant atezo improved disease-free survival (DFS) vs BSC in pts with PD-L1 tumour cell (TC) ≥1% stage II-IIIA NSCLC. While a … greenvale with vocalsWitryna10 wrz 2024 · IMpower010 (NCT02486718) enrolled patients with completely resected, stage IB to IIIA NSCLC with an ECOG performance status of 0 or 1, who had undergone lobectomy/pneumonectomy, and had tumor tissue available for PD-L1 analysis. If patients had stage IB tumors, they had to be 4 cm or greater. fnf keith\\u0027s momWitryna23 sie 2024 · The first pre-specified interim overall survival (OS) analysis of the phase 3 IMpower010 trial displayed a trend towards an OS benefit for patients with stage … fnf.kdata1.com refused to connect